High density lipoprotein (HDL)-associated sphingosine 1-phosphate (S1P) inhibits macrophage apoptosis by stimulating STAT3 activity and survivin expression

Feuerborn, Renata; Becker, Stefan; Potì, Francesco; Nagel, Petra; Brodde, Martin F.; Schmidt, H. H.-J.; Christoffersen, Christina; Ceglarek, Uta; Burkhardt, Ralph; Nofer, Jerzy–Roch

doi:10.1016/j.atherosclerosis.2016.12.009

Cited by 53 publications

(45 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The applicability of the optimized sample preparation procedure using N ‐ethylmaleimide as alkylating agent could be proved in a recovery study. Further, in a recent study of Nofer et al., expected concentration differences between apoM‐depleted and native human EDTA plasma could be confirmed using the presented methodology.…”

Section: Discussionsupporting

confidence: 62%

Targeted On‐line SPE‐LC‐MS/MS Assay for the Quantitation of 12 Apolipoproteins from Human Blood

et al. 2018

Self Cite

View full text Add to dashboard Cite

Laborious sample pretreatment of biological samples represents the most limiting factor for the translation of targeted proteomics assays from research to clinical routine. An optimized method for the simultaneous quantitation of 12 major apolipoproteins (apos) combining on-line SPE and fast LC-MS/MS analysis in 6.5 min total run time was developed, reducing the manual sample pretreatment time of 3 μL serum or plasma by 60%. Within-run and between-day imprecisions below 10 and 15% (n = 10) and high recovery rates (94-131%) were obtained applying the high-throughput setup. High-quality porcine trypsin was used, which outperformed cost-effective bovine trypsin regarding digestion efficiency. Comparisons with immunoassays and another LC-MS/MS assay demonstrated good correlation (Pearson's R: 0.81-0.98). Further, requirements on sample quality concerning sampling, processing, and long-term storage up to 1 year were investigated revealing significant influences of the applied sampling material and coagulant on quantitation results. Apo profiles of 1339 subjects of the LIFE-Adult-Study were associated with lifestyle and physiological parameters as well as establish parameters of lipid metabolism (e.g., triglycerides, cholesterol). Besides gender effects, most significant impact was seen regarding lipid-lowering medication. In conclusion, this novel highly standardized, high-throughput targeted proteomics assay utilizes a fast, simultaneous analysis of 12 apos from least sample amounts.

show abstract

Section: Discussionsupporting

confidence: 62%

Targeted On‐line SPE‐LC‐MS/MS Assay for the Quantitation of 12 Apolipoproteins from Human Blood

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Endothelial apoptosis may result in an increased permeability of vascular endothelium; in addition, dysregulated apoptosis of atherosclerotic plaque cells may be an unfavorable process leading to plaque instability [96,97], and HDL may attenuate this process. In fact HDL inhibit macrophage [98] as well as endothelial cell apoptosis induced by different stimuli [59,75,99,100]. ApoA-I and HDL-associated lysosphingolipids are the major components responsible for this effect [98,99,101].…”

Section: Hdl Structure Composition and Functionsmentioning

confidence: 96%

“…In fact HDL inhibit macrophage [98] as well as endothelial cell apoptosis induced by different stimuli [59,75,99,100]. ApoA-I and HDL-associated lysosphingolipids are the major components responsible for this effect [98,99,101]. HDL inhibits the apoptosis induced by several stimuli in endothelial cells [59,99], macrophages [102] and other cell types.…”

Section: Hdl Structure Composition and Functionsmentioning

confidence: 98%

Biological Consequences of Dysfunctional HDL

Pirillo

Catapano

Norata

2019

CMC

View full text Add to dashboard Cite

Epidemiological studies have suggested an inverse correlation between high density lipoprotein (HDL) cholesterol levels and the risk of cardiovascular disease. HDLs promote reverse cholesterol transport (RCT) and possess several putative atheroprotective functions, associated to the anti-inflammatory, anti-thrombotic and anti-oxidant properties as well as to the ability to support endothelial physiology. The assumption that increasing HDL-C levels would be beneficial on cardiovascular disease (CVD), however, has been questioned as, in most clinical trials, HDL-C-raising therapies did not result in improved cardiovascular outcomes. These findings, together with the observations from Mendelian randomization studies showing that polymorphisms mainly or solely associated with increased HDL-C levels did not decrease the risk of myocardial infarction, shift the focus from HDL-C levels toward HDL functional properties. Indeed, HDL from atherosclerotic patients not only exhibit impaired atheroprotective functions but also acquire pro-atherogenic properties and are referred to as "dysfunctional" HDL; this occurs even in the presence of normal or elevated HDL-C levels. Pharmacological approaches aimed at restoring HDL functions may therefore impact more significantly on CVD outcome than drugs used so far to increase HDL-C levels. Aims of this review is to discuss the pathological conditions leading to the formation of dysfunctional HDL and their role in atherosclerosis and beyond.

show abstract

“…First, apoA1 has been proved to negatively alter tumor-permissive features of tumor microenvironment through multiple pathways. These pathways include but are not limited to the following: suppressing the increase in myeloid-derived suppressor cells to decrease tumor volume [51]; reducing the matrix metalloproteinase-9 protein level and activity to inhibit tumor metastasis [52]; increasing the recruitments of tumor cell killing macrophages and CD8 T cells [53]; reducing the level of surviving, a anti-apoptotic protein, responsible for tumor regression [54]. Second, apoA1 and apoA1 mimetic peptides can bind pro-inflammatory or pro-angiogenic phospholipids, such as lysophosphatidic acid.…”

Section: Discussionmentioning

confidence: 99%

Association Between Pretreatment Serum Apolipoprotein A1 and Prognosis of Solid Tumors in Chinese Population: A Systematic Review and Meta-Analysis

Zhou

Zhang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Serum apolipoprotein A1 (apoA1) has been reported to be abnormally expressed in several malignancies. However, the prognostic role of apoA1 in solid tumors is still controversial. We conducted this meta-analysis to obtain a more accurate evaluation of prognostic significance of apoA1 in Chinese patients with solid tumors. Methods: A comprehensive literature search of electronic databases was carried out up to August 2018. We included studies investigating the association between pretreatment serum apoA1 level and clinicopathological features, including survival outcomes, in solid tumors. Hazard ratios (HRs) and odds ratio (ORs) with 95% confidence intervals (CIs) were applied as effect size estimates. Results: A total of 13 studies and 8052 patients were included in our meta-analysis. Elevated level of pretreatment serum apoA1 was markedly associated with an improved OS (pooled HR = 0.608, 95% CI = 0.557 – 0.665, P < 0.001). The statistical significances were observed in all cancer types, including digestive system malignancies (pooled HR = 0.633; 95% CI = 0.550–0.727; P < 0.001), urinary system cancers (pooled HR = 0.471; 95% CI = 0.352–0.630; P < 0.001), nasopharyngeal cancer (pooled HR = 0.642; 95% CI = 0.538–0.766; P < 0.001) and non-small cell lung cancer (pooled HR = 0.526; 95% CI = 0.329–0.841; P = 0.007), but not in breast cancer (pooled HR = 0.573; 95% CI = 0.266–1.246; P = 0.155). Meanwhile, cancer patients with a low level of serum apoA1 suffered an unfavorable DFS (pooled HR = 0.714, 95% CI = 0.603 – 0.845, P < 0.001). Moreover, abnormal serum apoA1 was significantly correlated to tumor size (pooled OR = 0.640, 95% CI = 0.475 – 0.863, P = 0.003), tumor differentiation (pooled HR = 0.724, 95% CI = 0.565 – 0.929, P = 0.011), and tumor stage (pooled HR = 0.493, 95% CI = 0.384 – 0.633, P < 0.001). Conclusion: Elevated level of pretreatment serum apoA1 was significantly associated with longer survival in patients with solid tumors. Pretreatment serum apoA1 could serve as a novel positive factor for malignant patient prognosis in Chinese population.

show abstract

High density lipoprotein (HDL)-associated sphingosine 1-phosphate (S1P) inhibits macrophage apoptosis by stimulating STAT3 activity and survivin expression

Cited by 53 publications

References 55 publications

Targeted On‐line SPE‐LC‐MS/MS Assay for the Quantitation of 12 Apolipoproteins from Human Blood

Targeted On‐line SPE‐LC‐MS/MS Assay for the Quantitation of 12 Apolipoproteins from Human Blood

Biological Consequences of Dysfunctional HDL

Association Between Pretreatment Serum Apolipoprotein A1 and Prognosis of Solid Tumors in Chinese Population: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About